REGULATORY

• Ishiba Hints at Reflecting Wage Hikes in Drug Pricing
  March 11, 2025

• Stelara to Get 40.8% Price Cut on PMP Return, Januvia Over 26% in 2025 Revision
  March 10, 2025

• Ishiba Flip-Flops on Copay Cap Hike, Drops Planned Raise in August
  March 10, 2025

• NARO Miniaturizes Immunodeficient Pigs for Use in Drug R&D
  March 10, 2025

• MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
  March 7, 2025

• Govt’s Regulatory Reform Panel Discusses Access to Clinical Trial Information
  March 7, 2025

• Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
  March 7, 2025

• New LDP Project Team Holds Hearing for Govt’s Startup Measures
  March 6, 2025

• CAR-T Therapies Subject to Label Revision over Lymphoid Neoplasm Risk
  March 6, 2025

• Safety-Related Label Revision Ordered for Trulicity, CP Inhibitors, and More
  March 6, 2025

• MHLW Taking Applications for Subsidies to Support Generic Consolidation, Biosimilars
  March 6, 2025

• Japan’s FY2025 Draft Budget Clears Lower House
  March 5, 2025

• Three-Party Talks to Be Held on Health Coverage of OTC-Like Drugs: Minister
  March 4, 2025

• No Prior Talks with US Drug Makers for Deferred PMP Price Cuts: Health Minister
  March 3, 2025

• Japan Grants Orphan Tags to Atrasentan, Efzimfotase, and Lots More
  March 3, 2025

• Japan to Revisit Copay Cap Hike Plan for 2026 and Beyond: Ishiba
  March 3, 2025

• Japan Extends Re-Examination Period for Zeposia, Lupkynis
  March 3, 2025

• Japan to Launch Pilot Project for Adopting Fair Market Value in Clinical Trial Costs
  February 28, 2025

• LDP Lawmakers Urge Generic Industry to Ramp Up Production
  February 28, 2025

• J&J’s Lazcluze, Genmab’s Tivdak and More Drugs in Line for Japan Approval
  February 28, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 27
• 28
• 29
• 30
• 31
• 32
• 33
• 34
• 35
• …
• Next ›
• 最終 »